Skip to content
Homepage
Author:
Verrica Pharmaceuticals Inc.
Posted Date:
June 22, 2026
Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
Verrica Pharmaceuticals Inc.
June 22, 2026
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
Verrica Pharmaceuticals Inc.
May 28, 2026
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Verrica Pharmaceuticals Inc.
May 13, 2026
Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results
Verrica Pharmaceuticals Inc.
May 12, 2026
Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting
Verrica Pharmaceuticals Inc.
May 5, 2026
Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026
Verrica Pharmaceuticals Inc.
May 5, 2026
Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference
Verrica Pharmaceuticals Inc.
April 6, 2026
Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results
Verrica Pharmaceuticals Inc.
March 11, 2026
Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026
Verrica Pharmaceuticals Inc.
March 5, 2026
Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
Verrica Pharmaceuticals Inc.
February 23, 2026
1
2
Next
